245 related articles for article (PubMed ID: 29319129)
1. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
2. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
Czepczyński R; Gryczyńska M; Ruchała M
Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
7. (99m)Tc HYNIC-TOC imaging and 177Lu DOTA-octreotate treatment in non-iodine-concentrating dedifferentiated thyroid carcinoma metastases: an unusual alternative diagnosis.
Basu S; Joshi A
Clin Nucl Med; 2014 Jul; 39(7):632-4. PubMed ID: 24873792
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
9. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
10. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
[TBL] [Abstract][Full Text] [Related]
11. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
12. [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma].
Czepczyński R; Kosowicz J; Ziemnicka K; Mikołajczak R; Gryczyńska M; Sowiński J
Endokrynol Pol; 2006; 57(4):431-5. PubMed ID: 17006849
[TBL] [Abstract][Full Text] [Related]
13. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
14. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
Hsu CH; Liu FY; Yen RF; Kao CH
Endocr Res; 2003 Feb; 29(1):9-15. PubMed ID: 12665314
[TBL] [Abstract][Full Text] [Related]
15. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
16. Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma.
Valsamaki P; Gotzamani-Psarrakou A; Tsiouris S; Molyvda-Athanasopoulou E; Psarrakos K; Papantoniou V; Gerali S; Zerva C
Int J Cancer; 2006 Aug; 119(4):968-70. PubMed ID: 16550594
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
18. Solitary hemorrhagic cerebellar metastasis from occult papillary thyroid microcarcinoma.
Lecumberri B; Alvarez-Escolá C; Martín-Vaquero P; Nistal M; Martín V; Riesco-Eizaguirre G; Sosa G; Pallardo LF
Thyroid; 2010 May; 20(5):563-7. PubMed ID: 20450434
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
20. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
